In the past 5 years, important advances have been made in the scientific understanding and
clinical management of cholangiocarcinoma (CCA). The cellular immune landscape of CCA …

Background: Immunotherapy has recently been incorporated into the spectrum of biliary tract
cancer (BTC) treatment. The identification of predictive response biomarkers is essential in …

Background HER2 is overexpressed or amplified in a subset of biliary tract cancer.
Zanidatamab, a bispecific antibody targeting two distinct HER2 epitopes, exhibited …

PURPOSE To evaluate the efficacy and safety of tucatinib and trastuzumab in patients with
previously treated human epidermal growth factor receptor 2–positive (HER2+) metastatic …

Abstract Background The TOPAZ‐1 phase III trial reported a survival benefit with the anti‐
programmed death cell ligand 1 (anti‐PD‐L1) durvalumab in combination with gemcitabine …

Background Therapeutic options in pre-treated advanced biliary tract cancer (BTC) are
limited. Although the ABC-06 trial demonstrated clinical benefit for mFOLFOX, there is an …

Purpose: BRAF mutations are rare in biliary tract cancers (BTC), but are of interest given the
recent developments in targeted therapy for BTC. We investigated the clinical outcomes in a …

Recent literature has significantly advanced our knowledge and understanding of the
cholangiocarcinoma tumor immune microenvironment. Detailed characterization of the …

Simple Summary Biliary tract cancers (BTCs), comprising cancers of the bile ducts
(cholangiocarcinoma) as well as gallbladder cancers, continue to be challenging to treat …

Simple Summary Biliary tract cancers (BTCs) are rare tumours associated with poor
prognosis. In advanced-stage disease, two treatment lines are approved: gemcitabine …